Recent studies by Zampaloni et al. and Pahil et al. published in the journal Nature describe a novel method of inhibiting the growth of Gram-negative bacteria such as Acinetobacter using antibiotics consisting of macrocyclic peptides that target the bacterial protein bridge machinery that transports lipopolysaccharides from the cytoplasm to the outer membrane.
ASCO 2024: Novartis’ Scemblix outperforms standard of care in CML
Novartis’ Scemblix generated $136m in sales in Q1 this year, as per the company’s financials. Image Credit: Taljat David / Shutterstock. Novartis has released positive